Canadian Anticoagulant Percutaneous Coronary Intervention Registry

Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00773006

Acronym

CAPCIR

Enrollment

747

Registered

2008-10-16

Start date

2008-02-29

Completion date

2011-09-30

Last updated

2011-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery disease, percutaneous coronary intervention, anticoagulation

Brief summary

Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease. However, the large diversity of approaches to anticoagulation during PCI introduces gaps in knowledge regarding management of cardiac patients. As such, we have initiated a national PCI registry to elucidate anticoagulant choice, dosing strategies, case selection dynamics, and clinical outcomes in the Canadian health care environment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. 18 or more years of age. 2. Undergoing PCI during treatment with LMWH 3. Provision of written and informed consent

Exclusion criteria

1. Language, medical, or psychiatric barriers that preclude understanding of informed consent process. 2. Patients in which the site investigator is unable to comply with completion of study documentation following PCI, i.e. patients with planned transfer to another hospital not participating in the registry. 3. Enrollment in a clinical trial involving another anticoagulant agent.

Design outcomes

Primary

Measure	Time frame
Description of anticoagulant management during PCI and current practices of participating centres will be undertaken	in-hospital

Secondary

Measure	Time frame
In-hospital safety outcomes including - major, minor bleeding, requirement for transfusion, death, myocardial infarction (or re-MI), myocardial ischemia requiring urgent revascularization, and major bleeding	in-hospital
In-hospital angiographic complications: no reflow, thrombus, occlusion of collateral branches, distal embolism, coronary dissection, acute closure of the culprit vessel	in-hospital
PCI-related resources utilization during the study period, including cost of PCI and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions)	in-hospital

Countries

Canada

Outcome results